메뉴 건너뛰기




Volumn 34, Issue 4, 2012, Pages 611-617

Evaluating real-life clinical and economical burden of amphotericin-B deoxycholate adverse reactions

Author keywords

Adverse effects; Amphotericin B; Antifungals; Cost effectiveness; Israel; Resource utilization

Indexed keywords

AMPHOTERICIN B DEOXYCHOLATE; ANTIFUNGAL AGENT;

EID: 84867404608     PISSN: 22107703     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11096-012-9654-y     Document Type: Article
Times cited : (10)

References (27)
  • 1
    • 0036178410 scopus 로고    scopus 로고
    • Amphotericin B: Spectrum and resistance
    • Ellis D. Amphotericin B: spectrum and resistance. J Antimicrob Chemother. 2002;49(Suppl 1):7-10.
    • (2002) J Antimicrob Chemother , vol.49 , Issue.SUPPL. 1 , pp. 7-10
    • Ellis, D.1
  • 2
    • 0035835901 scopus 로고    scopus 로고
    • Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: Randomised controlled trial
    • Eriksson U, Seifert B, Schaffner A. Comparison of effects of amphotericin B deoxycholate infused over 4 or 24 hours: randomised controlled trial. Br Med J. 2001;322:579-82.
    • (2001) Br Med J , vol.322 , pp. 579-582
    • Eriksson, U.1    Seifert, B.2    Schaffner, A.3
  • 3
    • 0036681666 scopus 로고    scopus 로고
    • Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: Animal experiments and clinical study
    • Mayer J, Doubek M, Doubek J, Horky D, Scheer P, Stepanek M. Reduced nephrotoxicity of conventional amphotericin B therapy after minimal nephroprotective measures: animal experiments and clinical study. J Infect Dis. 2002;186:379-88.
    • (2002) J Infect Dis , vol.186 , pp. 379-388
    • Mayer, J.1    Doubek, M.2    Doubek, J.3    Horky, D.4    Scheer, P.5    Stepanek, M.6
  • 5
    • 0037118677 scopus 로고    scopus 로고
    • Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS
    • Johnson PC, Wheat LJ, Cloud GA, Goldman M, Lancaster D, Bamberger DM, et al. Safety and efficacy of liposomal amphotericin B compared with conventional amphotericin B for induction therapy of histoplasmosis in patients with AIDS. Ann Intern Med. 2002;137(2):105-9.
    • (2002) Ann Intern Med , vol.137 , Issue.2 , pp. 105-109
    • Johnson, P.C.1    Wheat, L.J.2    Cloud, G.A.3    Goldman, M.4    Lancaster, D.5    Bamberger, D.M.6
  • 6
    • 0036177170 scopus 로고    scopus 로고
    • Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients
    • Cagnoni PJ. Liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Antimicrob Chemother. 2002;49(Suppl 1):81-6.
    • (2002) J Antimicrob Chemother , vol.49 , Issue.SUPPL. 1 , pp. 81-86
    • Cagnoni, P.J.1
  • 7
    • 33646836577 scopus 로고    scopus 로고
    • What is the current and future status of conventional amphotericin B?
    • Kleinberg M. What is the current and future status of conventional amphotericin B? Int J Antimicrob Agents. 2006;27(Suppl 1):12-6.
    • (2006) Int J Antimicrob Agents , vol.27 , Issue.SUPPL. 1 , pp. 12-16
    • Kleinberg, M.1
  • 9
    • 40649108887 scopus 로고    scopus 로고
    • Renal impairment and amphotericin B formulations in patients with invasive fungal infections [review]
    • Saliba F, Dupont B. Renal impairment and amphotericin B formulations in patients with invasive fungal infections [review]. Med Mycol. 2008;46:97-112.
    • (2008) Med Mycol , vol.46 , pp. 97-112
    • Saliba, F.1    Dupont, B.2
  • 10
    • 1942436895 scopus 로고    scopus 로고
    • Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies - A randomized, controlled trial
    • Subira M, Martino R, Gomez L, Marti JM, Estany C, Sierra J. Low-dose amphotericin B lipid complex vs. conventional amphotericin B for empirical antifungal therapy of neutropenic fever in patients with hematologic malignancies - a randomized, controlled trial. Eur J Haematol. 2004;72:342-7.
    • (2004) Eur J Haematol , vol.72 , pp. 342-347
    • Subira, M.1    Martino, R.2    Gomez, L.3    Marti, J.M.4    Estany, C.5    Sierra, J.6
  • 11
    • 0033545538 scopus 로고    scopus 로고
    • Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia
    • National Institute of Allergy and Infectious Diseases Mycoses Study Group
    • Walsh TJ, Finberg RW, Arndt C, Hiemenz J, Schwartz C, Bodensteiner D, et al. Liposomal amphotericin B for empirical therapy in patients with persistent fever and neutropenia. National Institute of Allergy and Infectious Diseases Mycoses Study Group. N Engl J Med. 1999;340:764-71.
    • (1999) N Engl J Med , vol.340 , pp. 764-771
    • Walsh, T.J.1    Finberg, R.W.2    Arndt, C.3    Hiemenz, J.4    Schwartz, C.5    Bodensteiner, D.6
  • 12
    • 0038282815 scopus 로고    scopus 로고
    • A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations [review]
    • Barrett JP, Vardulaki KA, Conlon C, Cooke J, Daza-Ramirez P, Evans EJ, et al. A systematic review of the antifungal effectiveness and tolerability of amphotericin B formulations [review]. Clin Ther. 2003;25:1295-320.
    • (2003) Clin Ther , vol.25 , pp. 1295-1320
    • Barrett, J.P.1    Vardulaki, K.A.2    Conlon, C.3    Cooke, J.4    Daza-Ramirez, P.5    Evans, E.J.6
  • 13
    • 4444253717 scopus 로고    scopus 로고
    • Amphotericin B: Is a lipidformulation gold standard feasible [letter]?
    • author reply 6-7
    • Spellberg B, Witt MD, Beck CK. Amphotericin B: is a lipidformulation gold standard feasible [letter]? Clin Infect Dis. 2004;38:304-5. author reply 6-7.
    • (2004) Clin Infect Dis , vol.38 , pp. 304-305
    • Spellberg, B.1    Witt, M.D.2    Beck, C.K.3
  • 14
    • 0035282477 scopus 로고    scopus 로고
    • Mortality and costs of acute renal failure associated with amphotericin B therapy
    • Bates DW, Su L, Yu DT, Chertow GM, Seger DL, Gomes DR, et al. Mortality and costs of acute renal failure associated with amphotericin B therapy. Clin Infect Dis. 2001;32:686-93.
    • (2001) Clin Infect Dis , vol.32 , pp. 686-693
    • Bates, D.W.1    Su, L.2    Yu, D.T.3    Chertow, G.M.4    Seger, D.L.5    Gomes, D.R.6
  • 15
    • 0034045794 scopus 로고    scopus 로고
    • Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients
    • Cagnoni PJ, Walsh TJ, Prendergast MM, Bodensteiner D, Hiemenz S, Greenberg RN, et al. Pharmacoeconomic analysis of liposomal amphotericin B versus conventional amphotericin B in the empirical treatment of persistently febrile neutropenic patients. J Clin Oncol. 2000;18:2476-83.
    • (2000) J Clin Oncol , vol.18 , pp. 2476-2483
    • Cagnoni, P.J.1    Walsh, T.J.2    Prendergast, M.M.3    Bodensteiner, D.4    Hiemenz, S.5    Greenberg, R.N.6
  • 17
    • 32144458558 scopus 로고    scopus 로고
    • Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes
    • Garbino J, Markham L, Matulionyte R, Rives V, Lew D. Should we continue using amphotericin B deoxycholate for the treatment of fungal infections? Adverse events and clinical outcomes. Scand J Infect Dis. 2006;38:110-3.
    • (2006) Scand J Infect Dis , vol.38 , pp. 110-113
    • Garbino, J.1    Markham, L.2    Matulionyte, R.3    Rives, V.4    Lew, D.5
  • 20
    • 0033062226 scopus 로고    scopus 로고
    • Must we really fear toxicity of conventional amphotericin B in oncological patients?
    • Mayer J, Doubek M, Vorlicek J. Must we really fear toxicity of conventional amphotericin B in oncological patients? Support Care Cancer. 1999;7:51-5.
    • (1999) Support Care Cancer , vol.7 , pp. 51-55
    • Mayer, J.1    Doubek, M.2    Vorlicek, J.3
  • 21
    • 33846973373 scopus 로고    scopus 로고
    • Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: Lower toxicity with suitable premedication
    • Oto OA, Paydas S, Disel U, Yavuz S, Seydaoglu G. Amphotericin B deoxycholate (d-AMB) use in cases with febrile neutropenia and fungal infections: lower toxicity with suitable premedication. Mycoses. 2007;50:135-9.
    • (2007) Mycoses , vol.50 , pp. 135-139
    • Oto, O.A.1    Paydas, S.2    Disel, U.3    Yavuz, S.4    Seydaoglu, G.5
  • 23
    • 60549098868 scopus 로고    scopus 로고
    • Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America
    • Pappas PG, Kauffman CA, Andes D, Benjamin DK Jr, Calandra TF, Edwards JE Jr, et al. Clinical practice guidelines for the management of candidiasis: 2009 update by the Infectious Diseases Society of America. Clin Infect Dis. 2009;48:503-35.
    • (2009) Clin Infect Dis , vol.48 , pp. 503-535
    • Pappas, P.G.1    Kauffman, C.A.2    Andes, D.3    Benjamin Jr., D.K.4    Calandra, T.F.5    Edwards Jr., J.E.6
  • 24
    • 3242782339 scopus 로고    scopus 로고
    • Empirical antifungal therapy in treating febrile neutropenic patients
    • Wingard JR. Empirical antifungal therapy in treating febrile neutropenic patients. Clin Infect Dis. 2004;39(Suppl 1):S38-43.
    • (2004) Clin Infect Dis , vol.39 , Issue.SUPPL. 1
    • Wingard, J.R.1
  • 25
    • 0035816268 scopus 로고    scopus 로고
    • Body surface area estimation in children using weight alone: Application in paediatric oncology
    • Sharkey I, Boddy AV, Wallace H, Mycroft J, Hollis R, Picton S. Body surface area estimation in children using weight alone: application in paediatric oncology. Br J Cancer. 2001;85:23-8.
    • (2001) Br J Cancer , vol.85 , pp. 23-28
    • Sharkey, I.1    Boddy, A.V.2    Wallace, H.3    Mycroft, J.4    Hollis, R.5    Picton, S.6
  • 26
    • 79952193176 scopus 로고    scopus 로고
    • Amphotericin B in neonates: Deoxycholate or lipid formulation as first-line therapy - Is there a 'right' choice?
    • Turkova A, Roilides E, Sharland M. Amphotericin B in neonates: deoxycholate or lipid formulation as first-line therapy - is there a 'right' choice? Curr Opin Infect Dis. 2011;24:163-71.
    • (2011) Curr Opin Infect Dis , vol.24 , pp. 163-171
    • Turkova, A.1    Roilides, E.2    Sharland, M.3


* 이 정보는 Elsevier사의 SCOPUS DB에서 KISTI가 분석하여 추출한 것입니다.